CORONA REMEDIES
Back to Cashflow Statement
|
CORONA REMEDIES Last 5 Year Cash Flow from Operating Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | |
|---|---|---|---|---|
| Cash Flow from Operating Activities | ₹229 Cr | ₹190 Cr | ₹157 Cr | ₹103 Cr |
What is the latest Cash Flow from Operating Activities ratio of CORONA REMEDIES ?
| Year | Cash Flow from Operating Activities |
|---|---|
| Mar2026 | ₹229 Cr |
| Mar2025 | ₹190 Cr |
| Mar2024 | ₹157 Cr |
| Mar2023 | ₹103 Cr |
How is Cash Flow from Operating Activities of CORONA REMEDIES Trending?
| Years | Cash Flow from Operating Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹229 Cr | 20.47 | |
| Mar2025 | ₹190 Cr | 21.52 | |
| Mar2024 | ₹157 Cr | 52.64 | |
| Mar2023 | ₹103 Cr | - | |
Compare Cash Flow from Operating Activities of peers of CORONA REMEDIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CORONA REMEDIES | ₹12,054.9 Cr | 6.6% | 17.6% | NA | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹449,299.0 Cr | 0.5% | 1.5% | 11.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹174,207.0 Cr | -3.3% | -3.5% | 1.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹157,721.0 Cr | 4.5% | 2.6% | 42.6% | Stock Analytics | |
| CIPLA | ₹117,420.0 Cr | 2.7% | 2.5% | -4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,876.0 Cr | 6.6% | 4.3% | 1.9% | Stock Analytics | |
CORONA REMEDIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CORONA REMEDIES | 6.6% |
17.6% |
|
| SENSEX | -0.1% |
1% |
-5.7% |
You may also like the below Video Courses